The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...
WXMI Grand Rapids, MI on MSN14h
Skin Envy explains Semaglutide and TirzepatideNone ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
A third drug, pretomanid, received emergency authorization from the FDA for specific use within a regimen against highly drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback